CN105311024B - Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug - Google Patents
Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug Download PDFInfo
- Publication number
- CN105311024B CN105311024B CN201410343687.9A CN201410343687A CN105311024B CN 105311024 B CN105311024 B CN 105311024B CN 201410343687 A CN201410343687 A CN 201410343687A CN 105311024 B CN105311024 B CN 105311024B
- Authority
- CN
- China
- Prior art keywords
- vasculitis
- drug
- oxymatrine
- kushenin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to kushenins（Oxymatrine, matrine, Iosmatrine）Pharmaceutically acceptable form or derivatives thereof, be used to prepare the application of prevention cutaneous vasculitis disease (including allergic cutaneous vasculitis, anaphylactoid purpura, erythema elevatum diutinum, acute febrile neutrophilic Dermatosis, urticarial vasculitis, pustular vasculitis, nodular polyarteritis, pyoderma gangraenosum, acidophilia vasculitis, eosinophilic cellulitis, Pigment purpura dermatitis, Wegner's granulomatosis, Behcet's disease, erythema nodosum, erythema induratum).
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of drug and is used to prepare answering in prevention and treatment cutaneous vasculitis disease
With.The drug is kushenin（Oxymatrine, matrine, Iosmatrine）Or its pharmaceutically acceptable form or derivatives thereof
And the medicine box containing the drug.
Background technology
Vasculitis refers to showing to obtain clinical pathology process by blood vessel and surrounding inflammation and necrosis.Its histopathologic change
The a series of change from simple mild necrosis vasculitis to granuloma can be presented.Infiltrating cells can be neutrophil leucocyte, lymph
Cell, eosinophil and histocyte etc..Due to involved vessels position, size, range, degree, inflammation and necrotic reaction
Etc. degree it is different, a variety of different performances are clinically presented.The cause of disease of cutaneous vasculitis is not yet fully apparent from.Possible cause of disease packet
It includes：1, it infects：Such as chronic tonsillitis, nasosinusitis, tympanitis, apical granuloma, cholecystitis, bronchitis, genito-urinary system
Togetherness dye, prostatitis, cervical lymphadenitis etc..These intralesional bacteriums make body sensitization.Also have been reported that fungal infection is
One of pathogenesis of vasculitis.Hepatitis virus, influenza virus, herpes simplex virus also may be related in the occurrence of this disease；2,
Drug, chemical substance, food etc.；3, with systemic disease：Such as connective tissue disease, malignant tumour, paraproteinemia；4,
A kind of autoimmune response caused by native blood vessel tissue antigen.The pathogenesis of vasculitis is more complicated, can there is immunity
And non-immunity pathogenesis, the overwhelming majority is accounted for immunity.
Currently, there is no good method to cutaneous vasculitis, the treatment of various cutaneous vasculitis is similar, lacks stronger
Specificity.Treatment includes the treatment technologies such as independent medication, drug combination.When state of an illness invasion development, treatment, which should surround, to be prevented to burst
Ulcer expands and prevents tissue damage from carrying out.It eliminates pathogenic factor or aggravates such as nervous, the cold and hot exposure of factor of disease also to pass
It is important.Antihistamine and non-steroid anti-inflammatory drug are effective to lighter lymphocytic vasculitis and urticarial vasculitis.Autumn waters -- limid eyes
Celestial alkali, dapsone and sulfapryidine are helpful to most lymphocytic vasculitis and cutaneous polyarteritis nodosa.Anti-malarial
Medicine may be effective to certain form of lymphocytic vasculitis, especially urticarial vasculitis.Glucocorticoid is treatment
The choice drug of lymphocytic vasculitis.Methopterin, cyclophosphamide, Chlorambucil, imuran and ciclosporin A etc. are exempted from
Epidemic disease inhibitor is usually used in the heavier case of the state of an illness.The vasculitis for being primary in thrombosis has anticoagulant or vasodilator agent
Effect, including niacinamide, low dosage aspirin, pentoxifylline, anti-coagulants and tissue plasminogen activator (t-PA) and calcium
Antagonism of ions agent (such as nifedipine).Vasculitis can give corresponding anti-infectious agent, such as antibiotic caused by infection, antiviral
Medicine etc., glucocorticoid should be used with caution or be disabled in the case of this, can be under the premise of application enough antipathogen medicines when being in a bad way
It is appropriate to use.When vasculitis characterized by immune complex is in a bad way, plasma exchange can be used and remove and exempt from blood plasma
Epidemic disease compound, protection patient tide over a critical period.Cell factor inhibitors or antagonist, anti-idiotype, monoclonal antibody and
The biological agents such as anti-endothelial cell adhesion molecule are used for refractory systemic cutaneous vasculitis.
Since the cutaneous vasculitis cause of disease is complicated, although there are many therapy, there are its limitation and adverse reaction, treats
Effect is nor highly desirable.
Kushenin with direct anti-inflammatory effect, immunoregulation effect, inhibition tumor proliferation, make by induction differentiation and apoptosis
With, anti-virus sterilizing effect, anti anoxia, expands blood vessel, reducing blood lipid, anti-arrhythmia, calmness, antipyretic, cooling, improves hemorheology
Learn indices effect.For the etiology and pathogenesis of cutaneous vasculitis disease incidence, in terms of cardiovascular system, oxymatrine tool
There is anti anoxia, expand the effects that blood vessel, reducing blood lipid, anti-arrhythmia.The direct anti-inflammatory effect that oxymatrine has：Matrine is
There is hormone-like effect and the strength anti-inflammatory agent without hormone side effect, kushenin（Oxymatrine, matrine）Direct anti-inflammatory work
It is reacted with can inhibit cutaneous vasculitis Disorders Inflammation；Oxymatrine has immunoregulation effect：Oxymatrine has relatively strong
Immunoregulation effect, can by the variation of antibody level, immunocyte to host, cell factor and other inflammatories adjust because
The influence of son plays its anti-inflammatory effect；Oxymatrine has inhibition tumor proliferation, induction differentiation and apoptotic effect；Oxymatrine
Anti-virus sterilizing effect：Oxymatrine has direct anti-virus sterilizing activity, and fungicidal spectrum is wider, anti-virus sterilizing
The cutaneous vasculitis disease that effect treats are caused by infection such as bacterium, viruses.
The present invention is provided by experiment for the etiology and pathogenesis for cutaneous vasculitis disease incidence, oxymatrine
Immunity-regulating react, direct anti-inflammatory effect, anti anoxia, expand blood vessel, it is anti-infective the effects that, to disease have toxic side effect it is low
Completely new drug, and its prepare for treating the application in cutaneous vasculitis disease.
Invention content
This invention people is by testing it has surprisingly been found that kushenin or derivatives thereof can provide particularly advantageous treatment skin
Vasculitis diseases act on, without observing apparent side effect.And this drug is particularly suitable for treating cutaneous vasculitis
Disease（Including allergic cutaneous vasculitis, anaphylactoid purpura, erythema elevatum diutinum, acute febrile neutrophilic Dermatosis, nettle
Measles vasculitis, pustular vasculitis, nodular polyarteritis, pyoderma gangraenosum, acidophilia vasculitis, acidophilia honeycomb
Knit inflammation, Pigment purpura dermatitis, erythema nodosum, erythema induratum etc.）Treatment.This drug can also combine existing technology
Such as：Hormone, immunosuppressor, immune protein, physical therapy, phototherapy.
The object of the present invention is to provide a kind of drugs for treating cutaneous vasculitis disease, and affiliated drug, which is given, can pharmaceutically connect
Measured or medicine effective dose kushenin（Oxymatrine, matrine, Iosmatrine）Or derivatives thereof, especially medicine
Object acceptable form or its pharmaceutical salts.
Kushenin or derivatives thereof content be 50 ~ 3000mg, further preferably 100 ~ 2000mg, more preferably 500 ~
1500mg。
Administration includes giving kushenin or derivatives thereof.Kushenin that the present invention provides or derivatives thereof drug scalar is
It is provided about compound itself, such as the kushenin of 100mg hydrochloride forms refers to the hydrochloride amount containing 50mg kushenins.
In the present invention, the drug can by by kushenin of above-mentioned content range or derivatives thereof in right amount pharmaceutically
After acceptable form is mixed with acceptable carrier, prepared according to the preparation method of conventional pharmaceutical preparation.
Kushenin or derivatives thereof is to distinguish in the form of pharmaceutical acceptable（Including pharmaceutically acceptable salt, ester
And solvate.）As pharmaceutically active agents administration.Kushenin of the present invention or derivatives thereof includes kushenin, Oxymatrine
Alkali, matrine, Iosmatrine or its officinal salt（Including hydrochloride, sulfate, acetate, phosphate, fumarate and each
Kind amino-acid salt）.
By the quality proportioning and corresponding auxiliary material can be added in the drug, be made be suitble to oral medication, drug administration by injection,
Percutaneous dosing, transmucosal absorb administration or the dosage form of other dosage forms.The drug can be prepared into big or low capacity note
The dosage forms such as agent, freeze-dried powder, aseptic powder packing are penetrated, can also be tablet, capsule, pulvis, dripping pill, pellet, particle, ingot
Agent, suppository, oral solution or sterile parenteral solutions or suspension formulation form or other dosage forms such as emulsion, paste etc..Liquid oral
Preparation can be the forms such as emulsion, syrup, can also be used as dry products presence, and water or other suitable carrier weights are used again using preceding
It is new to constitute.Auxiliary material includes（It is not limited to）Physiologically acceptable pharmaceutical excipient and pharmaceutic adjuvant.Wherein pharmaceutic adjuvant includes
One or more of sodium chloride, mannitol, PVP K30, glucose, lactose and combinations thereof.
In order to reach the consistency of administration, the present invention is preferably unit dose form.
For oral medication, containing pharmaceutically conventional excipient such as adhesive, for example (,) it is syrup, Arabic gum, bright
Glue, sorbierite, tragacanth, polyvinylpyrrolidone, hydroxypropyl methylcellulose, dextrin, polyethylene glycol etc.；Filler, such as lactose,
Sugar, cornstarch, calcium phosphate, sorbierite, glycine etc.；Tableting lubricant, such as magnesium stearate, polyethylene glycol etc.；Disintegrant,
Such as starch, polyvinylpyrrolidone, Explotab or microcrystalline cellulose；Pharmaceutically acceptable wetting agent, such as 12
Sodium alkyl sulfate etc.；Suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose
Element, aluminum stearate gel or hydrogenation eat ester etc.；Emulsifier, such as lecithin, anhydro sorbitol-oleate, Arabic gum
Deng；Anhydrous carrier（It may include edible oil）, such as apricot kernel oil, evaporating coconut oil or oily ester；Preservative, such as para hydroxybenzene
Methyl formate, propyl ester, sorbic acid etc.；Corrigent and sweetener, such as rebaudioside, Aspartame, Steviosin, xylitol, peppermint
Alcohol, flavoring orange essence etc.；Colorant etc. can also be added.Preparation method uses the preparation method of this field routine.
For parenteral, especially injection, unit liquid is prepared respectively at sterile carrier using active component
Dosage form, and be suspended or dissolved in carrier according to concentration used.When preparing liquid, active constituent can be dissolved in
Water for injection and filtration sterilization, are filled into container are sealed later.Advantageously, in order to be suitble to intravenous injection that can be added
The common adjuvant of injection such as preservative, acidity-basicity regulator, Osmolyte regulator, solubilizer, stabilizer, resists buffer
Oxygen agent etc..
In addition can also conventionally by drug single active ingredient or pharmaceutical composition sustained-release preparation is made, such as
Sustained release pellet or controlled release micro pill.
Preferably unit dose is made with the amount with relevant date appropriate dosage in the drug.Can be 1 ~ 6 time with daily administration, but most
It is preferred that being administered once daily（Drug administration by injection）Or 3 times（Oral medication and topical administration）.
According to the difference of administering mode and formulation requirements, the sum of kushenin and/or its derivative content can be in the drug object
It is the 0.1% ~ 99.9% of total amount.
The present invention is experimentally confirmed, and kushenin or derivatives thereof treatment cutaneous vasculitis disease effects are notable, and poison is secondary to be made
With slight.
Specific implementation mode
We illustrate the present invention in conjunction with the embodiments below.Following embodiment is merely to illustrate the technical side of the present invention
Case is not intended to limit the present invention.
Embodiment 1
The comparison that oxymatrine acts on Mouse Acute Toxicity
Kunming mice is randomly divided into Normal group and test medicine group, every group ten, half male and half female.Except Normal group
Outside, test medicine group is injected intraperitoneally respectively（ip）Large dosage of oxymatrine is primary, is observed continuously 7 days, records the death of animal
Time and death toll.
The results show that when the dosage of oxymatrine is 950mg/kg, there is larger toxicity, 9 death in 10 mouse.
Table oxymatrine, glycyrrhizic acid and combinations thereof（Ip is primary）Comparison to Mouse Acute Toxicity effect
| Group | Dosage（mg/kg） | Death toll/sum |
| Normal group | 0 | 0/10 |
| It is bitter | 950 | 9/10 |
Remarks：" hardship "：Indicate oxymatrine.
Embodiment 2
Oxymatrine Treating pigmentary purpura sample dermatitis clinical observation
1 data and method
1.1 clinical data clinical diagnosises meet 7 patients of pigmentary purpura sample dermatitis, man 4, female 3, age 24
~ 60 years old, systematic treating, no photosensitive diseases, the serious viscera disease such as no liver and kidney dysfunction, no work were not received in January
Dynamic property pulmonary tuberculosis, cataract medical history, reject the gestational period, women breast-feeding their children.
1.2 therapy intravenous drip Oxymatrine Injection 0.6g100ml/d；With 8 weeks as a treatment course, courses for the treatment of
Efficacy determination is carried out after afterwards.
1.3 curative effect determinate standard：Clinical recovery is 90% or more skin lesion recession after treatment；It is effective for skin lesion subside 60% ~
89%；Progress is skin lesion recession 20% ~ 59%；It is in vain 20% or less skin lesion recession.Effective percentage adds effective calculating with clinical recovery.
Check that blood urine is conventional, biochemical conventional before the treatment of 1.4 safety evaluatios, after each course for the treatment of（Including liver kidney function
Energy, blood glucose, electrolyte and blood fat）, and the adverse reaction occurred during treatment is recorded, serious adverse reaction occurs and exits observer
It is invalid to be judged to.
2 patients of result 7 fully recover 6, effective 1, total effective rate 100%.
3. 1 readme urine volume of adverse reaction increases；Pretherapy and post-treatment blood urine is routinely showed no apparent exception.
3. conclusion
Oxymatrine Treating pigmentary purpura sample dermatitis effects are notable, and effective percentage does not occur apparent bad anti-up to 100%
It answers.
Embodiment 3
The clinical observation of Oxymatrine Treating allergic cutaneous vasculitis
1 data and method
1.1 clinical data clinical diagnosises meet 3 patients of allergic cutaneous vasculitis, man 2, female 1, age 24
~ 33 years old, systematic treating, no photosensitive diseases, the serious viscera disease such as no liver and kidney dysfunction, no work were not received in January
Dynamic property pulmonary tuberculosis, cataract medical history, reject the gestational period, women breast-feeding their children.
1.2 therapy intravenous drip Oxymatrine Injection 0.6g100ml/d；With 6 weeks as a treatment course, courses for the treatment of
Efficacy determination is carried out after afterwards.
1.3 curative effect determinate standard：Clinical recovery is 90% or more skin lesion recession after treatment；It is effective for skin lesion subside 60% ~
89%；Progress is skin lesion recession 20% ~ 59%；It is in vain 20% or less skin lesion recession.Effective percentage adds effective calculating with clinical recovery.
Check that blood urine is conventional, biochemical conventional before the treatment of 1.4 safety evaluatios, after each course for the treatment of（Including liver kidney function
Energy, blood glucose, electrolyte and blood fat）, and the adverse reaction occurred during treatment is recorded, serious adverse reaction occurs and exits observer
It is invalid to be judged to.
2 patients of result 3 fully recover 2, effective 1, total effective rate 100%.
3. the pretherapy and post-treatment blood urine of adverse reaction is routinely showed no apparent exception.
3. conclusion
Oxymatrine Treating allergic cutaneous vasculitis significant effect, effective percentage do not occur apparent bad anti-up to 100%
It answers.
Embodiment 4
Oxymatrine 600mg
NaCl 0.9g
Appropriate water for injection
Every 100ml
NaCl is taken, with water for injection stirring and dissolving, oxymatrine is then added, continues to be completely dissolved when stirring, add
Water for injection is to total amount, filtration to clear and bright, potting, sterilizing to get.
Embodiment 5
Oxymatrine 200g
Sodium Hydroxymethyl Stalcs 10g
Lactose 50g
Magnesium stearate 0.5g
Appropriate pure water
It is made 1000
Oxymatrine crushed to 80 mesh sieve in advance, lactose is taken to cross 80 mesh sieve, it is spare.Take the above-mentioned fine powder of sieving by upper
It states prescription to weigh, is uniformly mixed, mixed powder is put into mixing machine, pure water is added while stirring, stirring is made for 15 minutes
Softwood, granulation, 50 ~ 60 DEG C of dryings of wet grain, whole grain, be added Sodium Hydroxymethyl Stalcs, magnesium stearate, mixing, tabletting to get.
Embodiment 6
Matrine 200mg
Microcrystalline cellulose 27.5mg
Lactose fruit-appropriate hydrate
Magnesium stearate 0.5mg
Film-making
After mixing by above-mentioned raw materials, auxiliary material, according to conventional wet lay
Embodiment 7：It is prepared by the powder-injection of drug
In sterile weighing area, 4g mannitol is claimed to be added in appropriate container, 800ml waters for injection, stirring is added to be allowed to abundant
Dissolving is added 50g kushenin stirring and dissolvings, 1000ml is injected water to, aseptically, with 0.22 μm of miillpore filter mistake
Dispensed after filter, loading amount be every bottle of 10ml, freeze-drying, add sterilizing fill in and roll outer cover to get.
Embodiment 8：The preparation of the freeze-dried powder of drug
Kushenin, oxymatrine, matrine, Iosmatrine
At normal temperatures and pressures, one of mentioned component is added in reagent bottle, is added well-known in the art suitable
Deionized water stirs, and fully dissolution system is concentrated under reduced pressure after dissolving；Secondly, water-soluble solvent is instilled under agitation, analyse
Go out white precipitate；Finally, being stirred under 50 DEG C of water bath conditions respectively makes transformation of crystal and stirs under room temperature to make crystallization
It completes, is filtered later, wash, the white crystals of one of mentioned component are made in the operating procedures such as 50 DEG C of vacuum drying；Or
It is freeze-dried by aqueous solution obtained above and freeze-dried powder is made.
Embodiment 9：It is prepared by the injection of drug
Kushenin, oxymatrine, matrine, Iosmatrine
One of mentioned component 50g is added in appropriate containers, the water for injection of addition total volume about 85%, stirring and dissolving,
PH value is surveyed, pH value about 6.0 ~ 6.5 is adjusted with hydrochloric acid solution or sodium hydroxide solution, 900g is added, stirring is allowed to dissolve, and filling is penetrated
With water to 10L, stirring make uniformly after with 0.22 μm of filtering with microporous membrane, rush nitrogen, embedding, 115 DEG C of pressure sterilizings 30 minutes, lamp
Inspection is examined, packaging.
Embodiment 10：
Oxymatrine 600mg
NaCl 0.9g
Appropriate water for injection
Sodium chloride water for injection stirring and dissolving is taken, it is to be completely dissolved day to be then respectively adding oxymatrine to continue stirring
Inject water to total amount, filtration to clear and bright, embedding, sterilizing to get.
Embodiment 11：It is prepared by the tablet of drug
Kushenin, oxymatrine, matrine, Iosmatrine
One of mentioned component 50g
Pregelatinized starch 2g
Hydroxypropyl cellulose 4g
Sodium carboxymethyl starch 3.5g
Microcrystalline cellulose 1g
Magnesium stearate 0.4g
One of mentioned component is crossed into 80 mesh sieve with above-mentioned each auxiliary material respectively, is uniformly mixed, has povidone that softwood is made, with 14
Mesh nylon mesh is pelletized, 50 ~ 60 DEG C of dryings, 14 mesh sieves, is carried out tabletting after mixing and is made.
It is prepared by the granule of 12 drug of embodiment
Kushenin, oxymatrine, matrine, Iosmatrine
One of mentioned component 50g
Honey element 8g
Lactose 8g
Appropriate essence
One of mentioned component is dissolved in water, starch 80g, Icing Sugar 20g is added, then flavoring essence is in right amount, mixing, with 14 ~ 16 mesh
Sieve granulation, 60 DEG C or less dryings, packaging.
Embodiment 13：It is prepared by the capsule of drug
Kushenin, oxymatrine, matrine, Iosmatrine
One of mentioned component 50g
Starch 5g
Microcrystalline cellulose 2g
Magnesium stearate 1g
One of mentioned component and above-mentioned each auxiliary material are sieved respectively, and are uniformly mixed, be sub-packed in hard capsule to get.
Embodiment 14：It is prepared by the oral solution of drug
Oxymatrine, matrine, Iosmatrine
One of mentioned component 50g
Propylene glycol 5g
Glycerine 1g
Gelatin 2g
Sucrose 10g
Sodium benzoate 0.1g
Citric acid 0.5g
Appropriate essence
Pure water 100g
After pure water is added with above-mentioned each auxiliary material in one of mentioned component, stirring and dissolving dispenses to obtain the final product.
Embodiment 15：It is prepared by the sustained release pellet of kushenin
Slow-released part prescription（Ball 1）
Capsule core prescription
Kushenin 200g
Microcrystalline cellulose 15g
Hydroxypropyl methylcellulose 5g
Pure water 200ml
It is made 1000
It is coated prescription
25% aqueous ethylcellulose dispersion liquid 184g
Pure water 123g
It is made 1000
Microcrystalline cellulose, kushenin be crushed into 80 mesh sieve in advance respectively, weighed by 1 prescription of ball, be uniformly mixed, hydroxypropyl first
Base cellulose aqueous solution makees adhesive, and pellet processed, by it in 50 ~ 60 DEG C of dryings, the piller of 20 ~ 30 mesh is spare.
The pellet that will be prepared and choose, sets in fluid bed, mode is sprayed the bottom of using, by hot-air suspension fluidization, into wind-warm syndrome
Degree is 55 DEG C, and at 30 DEG C, adjusting peristaltic pump makes it provide coating solution, mist by the speed of 5g slurries per minute for material bed tempertaure control
Change pressure 2bar, start continuously to whitewash to the piller of fluidisation, after whitewashing, reduce air quantity, make pellet under slight boiling condition in
40 DEG C of dry a moments.Taking-up is placed in 40 DEG C of baking ovens 24 hours dry, weightening about 18%, measure content to get.
Claims (2)
1. oxymatrine or its officinal salt are being prepared as sole drug active constituent with effective or recovery from illness effect treatment color
Application in the drug of the purpuric dermatitis of disposition, wherein fully recover for 90% or more skin lesion recession after treatment, effective skin after being treatment
Damage recession 60% ~ 89%.
2. according to the application described in claim 1, wherein officinal salt is hydrochloride, sulfate, acetate, phosphate, richness
Horse hydrochlorate or amino-acid salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410343687.9A CN105311024B (en) | 2014-07-18 | 2014-07-18 | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410343687.9A CN105311024B (en) | 2014-07-18 | 2014-07-18 | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105311024A CN105311024A (en) | 2016-02-10 |
| CN105311024B true CN105311024B (en) | 2018-11-13 |
Family
ID=55239988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410343687.9A Active CN105311024B (en) | 2014-07-18 | 2014-07-18 | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105311024B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770451A (en) * | 2016-04-25 | 2016-07-20 | 葛绍珍 | Traditional Chinese medicine for treating pigmentary purpura |
| CN105998687A (en) * | 2016-06-20 | 2016-10-12 | 刘艳 | Traditional Chinese medicine for treating allergic cutaneous vasculitis and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973560A (en) * | 2012-12-03 | 2013-03-20 | 施惠娟 | Novel method of applying matrine to treating eczematous dermatitis |
-
2014
- 2014-07-18 CN CN201410343687.9A patent/CN105311024B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973560A (en) * | 2012-12-03 | 2013-03-20 | 施惠娟 | Novel method of applying matrine to treating eczematous dermatitis |
Non-Patent Citations (3)
| Title |
|---|
| 氧化苦参碱对小鼠接触性皮炎的抑制作用;伍斌 等;《郑州大学学报(医学版)》;20060731;第41卷(第4期);第643-645页 * |
| 皮肤血管炎的免疫抑制治疗;张良芬;《中国麻风皮肤病杂志》;20011231;第17卷(第4期);第281-283页 * |
| 苦参及其生物碱对过敏性皮肤病的临床及实验研究;陈学荣 等;《医学研究通讯》;19991231;第28卷(第11期);第15-16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105311024A (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221563C2 (en) | Pharmaceutical composition for treatment of parkinson's disease and parkinson's syndrome, method for its preparing, method for treatment of parkinson's disease and parkinson's syndrome | |
| RU2616516C2 (en) | Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt | |
| CN104013592B (en) | Memantine sustained release pill and preparation method thereof | |
| CN103025317A (en) | Nalbuphine-based formulations and uses thereof | |
| CN103893247A (en) | Pharmaceutical composition as well as preparation method and application thereof | |
| CN107308130A (en) | Coated drugs orbicule and elimination reduce illness such as the purposes vomitted and suffered from diarrhoea | |
| ES2204517T3 (en) | COMPOSITIONS OF PHARMACEUTICAL CAPSULE CONTAINING LORATADINE AND PSEUDOEFEDRINE. | |
| ES2555927T3 (en) | Compositions of modified release of epalrestat or a derivative thereof and methods for using them | |
| CN105311024B (en) | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug | |
| WO2005034936A1 (en) | Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct | |
| CN106074463A (en) | Cannabidiol application in preparation treatment gouty arthritis medicine | |
| CN106511312A (en) | Compound sildennafil dapoxetine slow-release capsule and preparation method thereof | |
| EP2837380B1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| CN105311044B (en) | A kind of pharmaceutical composition is as the application in preparation treatment cutaneous vasculitis drug | |
| WO2020135491A1 (en) | Propafenone microtablet, multiple-unit dosage form comprising propafenone microtablet, and preparation methods therefor and uses thereof | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| CN105311025B (en) | Kushenin and its derivative are as the application prepared in treatment sterile pustular skin disease drug | |
| CN101657198A (en) | ranolazine for enhancing insulin secretion | |
| CN105287538B (en) | Kushenin and its derivative are as the application in preparation treatment lichen planus drug | |
| CN101574357A (en) | Prevention and treatment of diseases induced by microcirculation disturbance with panax notoginseng saponins R1 | |
| CN105311023B (en) | The pharmacy application of oxymatrine | |
| CN105311043B (en) | The application for preparing in drug of the composition in the preparation treatment dermotosis of metabolism disturbance | |
| CN105267227B (en) | A kind of pharmaceutical composition is as the application in preparation treatment sterile pustular skin disease drug | |
| CN105267228B (en) | A kind of pharmaceutical composition is as the application in preparation treatment neuropsychiatric disorders dermatoses drug | |
| CN101987200B (en) | Compound medicine containing antihypertensive peptide and aldosterone receptor antagonist for curing hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |